Quarterly ResultMay 7, 2026, 07:09 AM
Monte Rosa Q1 Net Loss $44.5M; Strong Pipeline Progress & Cash to 2029
AI Summary
Monte Rosa Therapeutics reported a net loss of $44.5 million for Q1 2026, a shift from a net income of $46.9 million in Q1 2025, with collaboration revenue decreasing to $4.2 million. Despite this, the company announced significant pipeline advancements, including positive interim data for MRT-8102 and MRT-2359, with multiple Phase 2 studies planned for these programs and MRT-6160. A strong balance sheet, bolstered by a $345 million public offering in January, provides a cash runway into 2029.
Key Highlights
- MRT-8102 GFORCE-1 trial showed 85% CRP reduction in CVD risk subjects.
- Multiple MRT-8102 Phase 2 studies to initiate from H2 2026 for inflammatory diseases.
- Novartis to initiate multiple Phase 2 studies for MRT-6160 in immune-mediated diseases in 2026.
- MRT-2359 Phase 1/2 data showed 100% disease control rate in 5 mCRPC patients with AR mutations.
- Q1 2026 net loss was $44.5 million, compared to $46.9 million net income in Q1 2025.
- Q1 2026 collaboration revenue was $4.2 million, down from $84.9 million in Q1 2025.
- Cash, cash equivalents, and marketable securities reached $671.2 million as of March 31, 2026.
- Cash runway extended into 2029 after $345 million public offering in January.